The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
---- Acknowledgements -----
We are grateful to Patricia Danzon, Richard Frank, Scott Harrington, Sean Nicholson, Mark Pauly, Stephen Propper, Fiona Scott-Morton, Steven Teutsch and participants at the 2nd American Society of Health Economists meetings and the 2008 annual meeting of the Southern Economic Association for helpful comments. Phil Saynisch provided exceptional research assistance. We would also like to acknowledge the Blanche and Irwin Lerner Center for Pharmaceutical Management Studies at the Rutgers University Business School for the IMS data. Financial support from the Merck Foundation to University of Pennsylvania is gratefully acknowledged. The views expressed herein are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic Research.